SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment (Intervention)
Recruiting now · Not applicable
Conditions studied: Gastrointestinal Cancer, Hematologic Cancer, Thoracic Cancer
In brief
SURGE aims to increase equity in clinical trial enrollment by addressing barriers to genomic testing, which is increasingly needed to assess precision clinical trial eligibility and access standard precision therapies. The study is an interventional pilot meant primarily to assess the feasibility of the intervention. The intervention is comprised of a patient navigator, text message questionnaire, and informational video.
Key facts
- Study ID
- NCT05375643
- Run by
- Nadine McCleary, MD, MPH
- People needed
- 210
- Starts
- 2023-04-03
- Expected to finish
- 2028-07-30
- Last updated by the study team
- 2025-11-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adult (age 18 years or older)
- Black, Latinx, OR older adult (age 70 years or older)
- Scheduled for a new patient consultation
- Suspected or confirmed advanced malignancy (requiring active treatment)
- Gastrointestinal, hematologic, or thoracic cancer
- DFCI patient at Longwood/Chestnut Hill, DFCI satellite at St. Elizabeth's Medical Center, or DFCI satellite at Merrimack Valley
You may not qualify if…
- Malignancy or former malignancy that requires only surveillance
- Not continuing care at a participating DFCI site
- Speaks a language other than English or Spanish
- Unable to provide consent
Where it is running
- Dana Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
- Dana-Farber Cancer Institute at St. Elizabeth's Medical Center — Brighton, Massachusetts, United States (enrolling)
- Dana-Farber Cancer Instiute - Merrimack Valley — Methuen, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.